CD8A and neoplasm: Immune checkpoint blockade (ICB) therapy, a critical category of immunotherapy, operates by inhibiting signals that suppress T-cell activation, thereby facilitating tumor-reactive T-cells to effectively combat tumors (60).In-depth analyses were performed to explore differences in the immune microenvironment among subtypes of the CD8+ T-cell activation model.